As part of a continued push to lay the groundwork for a commercial launch in 2016, digital health business Cohero Health closed a $2 million Seed round, according to a company statement. It expects to launch its smartphone enabled remote monitoring device for patients with asthma and for patients with chronic obstructive pulmonary disease in the second quarter next year.
In addition to Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts, and Bioadvance, investors included Three Leaf Ventures — an affiliate of the Broe Group, Swanhill Capital and StartUp Health through its digital health syndicate on AngelList. Cohero Health is a member of StartUp Health Academy a three year program to support health tech startups.
The statement noted that early results showed a 2.5 times increase in medication adherence over standard of care, and a 100 percent reduction in hospitalizations.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Among Three Leaf’s other investments are Scanadu, diagnostics business HealthTell and genetic testing business Invitae.
SwanHill Capital appears to have a broader range of investments including patient-care team communication platform developer Conversa Health, RxREVU —a company that uses analytics to help identify the most effective medication at affordable pries company that to non-skilled home care staffing agency SupportiveCare Cohero developed a device to do remote monitoring for lung functions and medication adherence. It was cleared by the U.S. Food and Drug Administration in June for patients with asthma and for patients with chronic obstructive pulmonary disease COPD.
Photo: Cleveland Clinic (featured), Cohero Health
